Frontage offers full-service radiolabeled human C14 AME (hAME) studies to support your drug development programs.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
Frontage's Clinical and DMPK teams work together seamlessly to provide full-service radiolabeled human C14 AME (hAME) studies. Experience the benefits and added value of Frontage’s complete suite of clinical and analytical services for hAME studies - seamless conduct and precise analysis by the most client-focused experts in the industry.
Fascin is an actin-bundling protein that has been linked to tumor cell migration, invasion, metastasis, disease progression and mortality, thus serving as a novel cancer biomarker. In this paper, we develop and validate an LC-MS/MS method for the quantification of fascin proteins in human serum.
The microbiome continuously shapes its environment through a complex set of interactions, and the microbial flora within and outside the human body has an essential relationship to an organism’s health status. For instance, dysbiosis in the gut microflora is an established contributor to the development of pathological conditions such as chronic inflammatory bowel diseases, type 2 diabetes, and colorectal cancer. In the drug discovery industry, scientists must be proactive in detecting changes in the intestinal microbiome in response to novel therapeutics. Changes to the microbiome associated with probiotic and prebiotic administration must be carefully monitored. Characterizing changes to the gut microbiome whether by metabolic, enzymatic, biomarker, or genomic approaches is fraught with difficulty and has a high assay development and validation cost. Therefore, many companies have looked to partner with research organizations that have success with innovative microbiome analysis tools.
In this webinar, our distinguished speakers, Dr. David Kwok and Dr. David Willoughby discuss current biomarker identification and metabolic evaluation techniques of the human gut microbiome, as well as metagenomic sequencing modalities utilized to streamline results for expedited interpretation and analysis.